Lymphoma News

A fourth dose of the COVID-19 vaccine increased humoral immunity among patients with solid and hematologic cancers, according to study results published in JAMA Oncology.

The basic science discoveries to which Helen E. Heslop, MD, DSc (Hon), has contributed place her firmly on the Mount Rushmore of pioneers in the field of gene and cell therapy.

The FDA granted regenerative medicine advanced therapy designation to CTX130, a chimeric antigen receptor T-cell therapy under development for the treatment of mycosis fungoides and Sézary syndrome.

Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has allowed those who require treatment to benefit from the groundbreaking development of chimeric antigen receptor T cells.

Anxiety and depression that may follow a cancer diagnosis, especially as a patient approaches the end of life, can be incapacitating and difficult to assuage.

An FDA advisory panel voted 8-4 that duvelisib did not have a favorable benefit-risk profile for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior therapies.

It is well known that obesity, physical inactivity and a poor diet increase the risk for various cancer types and contribute to adverse outcomes among adults with certain malignancies.

Gerontology researchers and hematologic oncology investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute have devised a scale for assessing high-risk medications in older patients with blood cancers.

A novel multicancer early detection blood test identified a common signal for more than 50 cancer types and predicted where the signal originated in the body among individuals with undiagnosed cancer.

September is Childhood Cancer Awareness Month.